|
|
|
School
|
Status
|
Round
|
Year
|
GMAT
GRE
|
GPA
|
YOE
Years of Experiance
|
Post-MBA industry
|
Location
|
Date
|
|---|---|---|---|---|---|---|---|---|---|
|
Stern
Full Time MBA |
Waitlisted with Interview
|
Round 1 | 2025 | 715 GMAT Focus | 3.6 | 7 | Pharmaceuticals and Biotech | United States |
12 Dec 2024 03:00 PM
|
|
Fuqua
Full Time MBA |
Waitlisted with Interview
|
Round 1 | 2025 | 615 GMAT Focus 675 GMAT Focus |
3.2 | 7 | Consulting | United States |
12 Dec 2024 02:36 PM
|
|
Haas
Full Time MBA |
Denied with Interview
|
Round 1 | 2025 | 327 GRE | 3.4 | 5 | Computer Software | United States |
12 Dec 2024 02:34 PM
|
|
Fuqua
Full Time MBA |
Admitted, ($)
|
Round 1 | 2025 | 3 | Finance | India |
12 Dec 2024 02:29 PM
|
||
|
Fuqua
Full Time MBA |
Waitlisted with Interview
|
Round 1 | 2025 | 740 GMAT Classic | 3.5 | 5 | Real Estate | United States |
12 Dec 2024 02:15 PM
|
|
Fuqua
Full Time MBA |
Denied with Interview
|
Round 1 | 2025 | 655 GMAT Focus 680 GMAT Classic |
3.4 | 5 | Finance: Investment Banking | United States |
12 Dec 2024 02:13 PM
|
|
Fuqua
Full Time MBA |
Waitlisted with Interview
|
Round 1 | 2025 | 730 GMAT Classic | 3.2 | 6 | Finance: Investment Banking | United States |
12 Dec 2024 02:11 PM
|
|
Fuqua
Full Time MBA |
Waitlisted with Interview
|
Round 1 | 2025 | 665 GMAT Focus | 3.7 | 0 | Finance | United States |
12 Dec 2024 02:08 PM
|
|
Sloan MIT
Full Time MBA |
Admitted
|
Round 1 | 2025 | 615 GMAT Focus | 3 | Other | Italy |
12 Dec 2024 01:52 PM
|
|
|
IMD
Full Time MBA |
Admitted, ($)
|
Round 4 | 2025 | 316 GRE | 3 | 10 | Finance | Brazil |
12 Dec 2024 01:09 PM
|
|
HEC Paris
September Intake |
Admitted, ($)
|
Round 2 | 2025 | 316 GRE | 3 | 10 | Finance | Brazil |
12 Dec 2024 01:09 PM
|
|
Anderson
FEMBA |
Admitted
|
Round 1 | 2025 | Waiver | 3.8 | 5 | Consulting | United States |
12 Dec 2024 01:09 PM
|
|
Stern
Full Time MBA |
Waitlisted with Interview
|
Round 1 | 2025 | 6 | Pharmaceuticals and Biotech | United States |
12 Dec 2024 12:53 PM
|
||
|
Kellogg
Full Time MBA |
Waitlisted without Interview
|
Round 1 | 2025 | 327 GRE 331 GRE |
7.3 | 9 | Finance: Investment Banking | India |
12 Dec 2024 12:41 PM
|
|
Sloan MIT
Full Time MBA |
Admitted, ($$)
|
Round 1 | 2025 | 685 GMAT Focus | 3.8 | 0 | Pharmaceuticals and Biotech | United States |
12 Dec 2024 12:20 PM
|
|
Fuqua
Full Time MBA |
Admitted, ($)
|
Round 1 | 2025 | 158 EA | 8 | Commercial Banking | Brazil |
12 Dec 2024 12:13 PM
|
|
|
Sloan MIT
Full Time MBA |
Admitted
|
Round 1 | 2025 | 690 GMAT Classic | 3.3 | 4 | Consulting | Mexico |
12 Dec 2024 11:44 AM
|
|
Kellogg
Full Time MBA |
Admitted, ($$)
|
Round 1 | 2025 | 730 GMAT Classic | 3.8 | 4 | Other | United States |
12 Dec 2024 11:20 AM
|
|
Sloan MIT
Full Time MBA |
Denied without Interview
|
Round 1 | 2025 | 3.6 | 10 | Pharmaceuticals and Biotech | United States |
12 Dec 2024 10:56 AM
|
|
|
Fuqua
Full Time MBA |
Admitted
|
Round 1 | 2025 | 3.6 | 10 | Pharmaceuticals and Biotech | United States |
12 Dec 2024 10:56 AM
|